Target
Nab-Paclitaxel
50 abstracts
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
A distinct dimension of immunotherapeutic biomarker: Beyond immune infiltration and tumor antigenicity.Org: Zhongshan School of Medicine,
Abstract
Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy in local advanced nasopharyngeal carcinoma.Org: The Affiliated Hospital of Guangdong Medical University,
Abstract
Efficacy and safety of the combination of tisleizumab with chemoradiotherapy in oligorecurrence esophageal squamous cell carcinoma: A prospective phase II study.Org: Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.Org: Florida Cancer Specialists North Division, Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), IPSEN Bioinnovation Limited, Università degli studi di Verona and Azienda Ospedaliera Universitaria Integrata,
Abstract
Pyrotinib plus taxanes or vinorelbine for human epidermal growth factor receptor 2-positive metastatic breast cancer: A prospective study.Org: Imaging Department, Jiangsu Cancer Hospital Medical Oncology, Jiangsu Cancer Hopistal,
Abstract
Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.Org: Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain, Yale University School of Medicine, New Haven, CT, Sheba Medical Center, Ramat Gan, and Tel Aviv University, Tel Aviv, Israel, Rambam Medical Center, Haifa, Israel, HonorHealth Research Institute, Scottsdale, AZ,
Abstract
Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).Org: Ramat Gan, Hadassah Hebrew - University Medical Center, Jerusalem, Medical Oncology and Immunotherapy, Siena,
Abstract
Phase II study of pirfenidone combined with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.Org: Department of Pancreatobiliary Surgery,
Abstract
GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS.Org: Chirurgia Digestiva, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Wallace McCain Center for Pancreatic Cancer,
Abstract
VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer.Org: Vall d´Hebrón Institute of Oncology (VHIO),
Abstract
A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.Org: Liaoning Cancer Hospital, Shenyang, China, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Yunnan Cancer Hospital, Yunnan, China, CSPC Ouyi Pharmaceutical Technology (Shijiazhuang) Co.,Ltd, Shijiazhuang, China,
Abstract
A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).Org: Department of Thoracic Surgery and Lung Cancer Center, Pathologic Department,
Abstract
Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma.Org: 1440 Foundation,
Abstract
J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients (pts) with non-small cell lung cancer (NSCLC) in Japan.Org: Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan, Department of Thoracic Oncology, Kansai Medical University, Osaka, Japan, Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Fukujuji Hospital, Tokyo, Japan, Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan,
Abstract
Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.Org: Concr LTD, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow,
Abstract
A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, Guangdong, China,
Abstract
The preliminary efficacy and safety results of neoadjuvant phase 2 study of penpulimab combined with taxanes and carboplatin in triple-negative breast cancer (neoTAPPL).Org: Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Sounthwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Thoracic Surgery, the Eighth Medical Center of Chinese PLA General Hospital, Chongqing, China, Central Medical Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L., Nanjing, China,
Abstract
Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.Org: Actuate Therapeutics, Inc., Courante Oncology,
Abstract
A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin.Org: Zhengzhou University First Affiliated Hospital, Jiangsu Hengrui Pharmaceuticals Co.,Ltd,
Abstract
Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.Org: Mayo Clinic, Actuate Therapeutics, Inc., Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Legorreta Cancer Center at Brown University,
Abstract
ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma.Org: NewYork-Presbyterian/Weill Cornell Medical Center,
Abstract
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.Org: New York University, Grossman School of Medicine, New York University, School of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Efficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trial.Org: Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Efficacy and safety of sitagliptin, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).Org: Tiianjin,
Abstract
Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study.Org: The University of Tokyo, Tokyo, Japan, National Cancer Center Hospital Japan East, Kashiwa, Japan, Sapporo Medical University Hospital, Sapporo-Shi, Japan, Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, Shizuoka Cancer Center, Nagaizumi, Japan,
Abstract
Predictive value of baseline 68Ga‑FAPI PET/CT in the first-line therapy of pancreatic ductal adenocarcinoma (PDAC).Org: Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis.Org: Dept of Oncology, Research Institute and Hospital, National Cancer Center, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Nucleus Network,
Abstract
Neoadjuvant pembrolizumab/nab-paclitaxel/cisplatin in patients with locally advanced head and neck squamous cell carcinoma: A single-arm phase II study.Org: Guangdong Provincial People‘s Hospital,
Abstract
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).Org: Columbus, OH, GZA-ZNA Hospitals, Joan and Sanford I Weill Medical College of Cornell University, Weill Cornell Medicine, New York, NY,
Abstract
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.Org: Memorial Sloan Kettering Cancer Center, Azienda Ospedaliera Universitaria Integrata di Verona, Hospital Universitario Miguel Servet, Centre Léon Bérard, Masaryk Memorial Cancer Institute,
Abstract
Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University of California San Francisco, UCSF Medical Center, Helen Diller Family Comprehensive Cancer Center, University of California Comprehensive Cancer Center,
Abstract
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,
Abstract
A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.Org: Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Department of Otolaryngology Head and Neck Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University,
Abstract
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.Org: USF Health Morsani College of Medicine, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Fellowship (GME Office), Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, MSKCC,
Abstract
Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.Org: Sarah Cannon Research Institute and Sidney Kimmel Cancer Center, Thomas Jefferson University, Thomas Jefferson University, START Midwest, Grand Rapids, MI, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, START San Antonio,
Abstract
Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).Org: Copenhagen University Hospital - Herlev and Gentofte, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN,
Abstract
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.Org: Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China, Women's Hospital School of Medicine Zhejiang University,
Abstract
Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer.Org: Mayo Clinic Florida, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), Karmanos Cancer Institute, Hoag Family Cancer Institute and University of Southern California,
Abstract
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).Org: Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany, Bruederkrankenhaus St. Josef Paderborn, Technical University Munich, Universitätsklinikum Freiburg Klinik Für Innere Medizin II Gastrointestinale Onkologie, Onkologische und Hamatologische Schwerpunktpraxis,
Abstract
Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, University of Michigan Health System Comprehensive Cancer Center, Hospital Universitari Vall d'Hebron Research Institute, Roswell Park Cancer Institute,
Abstract
LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.Org: Department of Hematology Oncology University of Illinois of Chicago College of Medicine, University of Ilinois Chicago, Department of Surgery University of Illinois of Chicago College of Medicine, University of Illinois Chicago, Jesse Brown VAMC,
Abstract
Oncologists’ receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services.Org: Memorial Sloan Kettering Cancer Center, Vanderbilt University School of Medicine, DELFI Diagnostics, Medical College of Wisconsin,
Abstract
Gemcitabine, cisplatin, nab-paclitaxel: The effectiveness of this regimen for gall bladder cancer.Org: Tata Memorial Hospital (HBNI), Tata Memorial Centre, Tata Memorial Center (HBNI),
Abstract
The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer.Org: Amplia Therapeutics, Melbourne, Australia, Australian Catholic University, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia,
Abstract
Efficacy and safety of second-line treatment for advanced gastric cancer: A network meta-analysis of randomized controlled trials.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,
Abstract
Efficacy and safety of nab-paclitaxel+cisplatin/nedaplatin + S-1 as an induction chemotherapy regimen for locally advanced hypopharyngeal cancer.Org: Affiliated Hospital of Guilin Medical University, Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University,
Abstract
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): A single-arm, phase Ⅱ trial.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Gastrointestinal Surgery Center, Department of Gastroenterology and Urology, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Clinical outcomes of patients who are frail and elderly with unresectable pancreatic ductal adenocarcinoma (PDAC) treated with chemotherapy.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Morningside-West, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, New York, NY, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, NY, NY, Mount Sinai Health System, NY, NY, Icahn School of Medicine at Mount Sinai, New York, NY,
Abstract
Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, University of Pittsburgh Medical Center (UPMC), Department of Medicine, Icahn School of Medicine at Mount Sinai,